SOPHiA GENETICS (SOPH) to Release Quarterly Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is scheduled to release its earnings data before the market opens on Tuesday, November 5th. Analysts expect SOPHiA GENETICS to post earnings of ($0.24) per share for the quarter. SOPHiA GENETICS has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. The business had revenue of $15.81 million during the quarter, compared to the consensus estimate of $17.58 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Trading Up 1.7 %

NASDAQ SOPH opened at $3.64 on Friday. The firm’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $4.26. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.17 and a current ratio of 4.40. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $7.37. The stock has a market cap of $237.98 million, a price-to-earnings ratio of -3.57 and a beta of 1.03.

Analyst Upgrades and Downgrades

SOPH has been the topic of a number of research analyst reports. Royal Bank of Canada lowered their price target on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley cut SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $10.00 to $5.00 in a research note on Wednesday, August 7th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.